Rx Pricing, Rebating Should Be Back To Business As Usual In 2020, PBMs Say
Political focus of drug pricing debate has shifted away from pharmacy benefit managers, CVS Health’s Merlo suggests.
You may also be interested in...
PhRMA CEO Steven Ubl offers list of policy alternatives to drug pricing bills pending in the US Congress that he argues would stifle innovation; industry's plans, on the other hand, could produce "meaningful" legislation.
Legislation redirecting manufacturer rebates on prescription drugs to the point of sale could face an uphill battle following report’s description of the way rebates lower costs in Medicare Part D.
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.